Accessibility Menu
Daré Bioscience logo

Daré Bioscience

(NASDAQ) DARE

Current Price$1.94
Market Cap$29.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-97%
5 Year-89%
1 Year-22%
1 Month-6%
Daré Bioscience last closing stock price
MetricPriceDate
Last closeUSD 1.962026-07-17
Daré Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.97%USD 2.022026-07-10
1 month-5.77%USD 2.082026-06-17
3 month-33.56%USD 2.952026-04-17
Year to date+1.55%USD 1.932025-12-31
1 year-21.6%USD 2.502025-07-17
3 year-80.32%USD 9.962023-07-18
5 year-88.89%USD 17.642021-07-16
Since inception-97.28%USD 72.002017-07-20

Daré Bioscience Financials at a Glance

Market Cap

$29.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.16M

Net Income (TTM)

-$12.02M

EPS (TTM)

-$1.04

P/E Ratio

-1.89

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$1.94

Volume

100,932

Open

$1.95

Previous Close

$1.96

Daily Range

$1.90 - $1.98

52-Week Range

$1.27 - $3.78

Estimated Earnings Date

Aug 13, 2026

DARE News

Foolcom-Featured.png

Daré Bioscience Posts Narrower Q2 Loss

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daré Bioscience

Daré Bioscience develops medicines for women’s health needs in the U.S. Its products address contraception, sexual health, and vaginal infections. These treatments help women manage everyday health issues with simple, targeted solutions.

Products and Services

  • XACIATO vaginal gel: Treats bacterial vaginosis in females aged 12 and older; 100% of revenue in Q2 2025.
  • Ovaprene contraceptive: Hormone-free, monthly vaginal birth control; in late-stage clinical testing.
  • Sildenafil Cream: Topical cream for female sexual arousal disorder; in advanced clinical development.
  • Hormone therapy rings: Intravaginal rings for menopause symptoms and preterm birth prevention; early clinical stages.
  • Preclinical contraceptives: Injectable and non-hormonal options for long-term or reversible birth control; not yet in human trials.

Growth and Expansion

  • Partnered with Organon in 2022 to commercialize XACIATO in the U.S.
  • Licensed Ovaprene U.S. rights to Bayer HealthCare in 2020; pivotal study ongoing.
  • Launched dual-path strategy (FDA approval and compounding) in March 2025 for faster product access.
  • Secured major grants: $49M for DARE-LARC1 (2021–2026), $10.7M for Ovaprene (2024–2026).
  • Expanded into consumer health with planned vaginal probiotics and compounded Sildenafil Cream in 2025.

What Makes Daré Stand Out

Daré uses partnerships for product launches, avoiding the need for its own sales force. The company relies on grants and non-dilutive funding to support research, reducing dependence on equity sales. Its focus is on women’s health areas with few new treatment options.

Five Things You Need to Know

  • Q2 2025 revenue was $(21,172), down 194.4% from Q2 2024.
  • Net loss for Q2 2025 was $4.0M, compared to $12.9M net income in Q2 2024.
  • Operating expenses fell 48% year-over-year in Q2 2025.
  • All Q2 2025 unrestricted cash and cash equivalents ($5.0M) were funds received under grant agreements that may be applied solely toward direct costs for the funded projects under those grant agreements, with an approximately 5% to 22% indirect cost allowance.
  • Working capital deficit reached $12.6M as of June 30, 2025.

Bottom Line

Daré has evolved by focusing on partnerships, grants, and targeted women’s health products. The company faces financial challenges but continues to pursue new solutions in underserved markets.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

24

CEO

Sabrina Martucci Johnson, MBA

Website

www.darebioscience.com

Headquarters

San Diego, CA 92122, US

DARE Financials

Key Financial Metrics (TTM)

Gross Margin

-95.98%

Operating Margin

-1034.38%

Net Income Margin

-1038.77%

Return on Equity

763.44%

Return on Capital

-246.47%

Return on Assets

-43.20%

Earnings Yield

-52.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$29.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.98M

Volume

100.93K

Avg. Volume

432.87K

Financials (TTM)

Gross Profit

-$1.11M

Operating Income

-$11.97M

EBITDA

-$9.52M

Operating Cash Flow

-$9.94M

Capital Expenditure

-$227.95K

Free Cash Flow

-$10.16M

Cash & ST Invst.

$18.52M

Total Debt

$1.61M

Daré Bioscience Performance Analysis

Daré Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 10,000,000N/A
20232023-12-31USD 2,807,885-71.9%
20242024-12-31USD 9,784-99.7%
20252025-12-31USD 1,030,19310429.4%
Daré Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-183.3%
Q32025-09-30110.7%
Q42025-12-3145155.3%
Q12026-03-31-85.1%
Daré Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.39-42.2%
20232023-12-31USD -4.15-5.6%
20242024-12-31USD -0.48-88.5%
20252025-12-31USD -1.20151.3%
Daré Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.0%
Q32025-09-3037.8%
Q42025-12-3164.5%
Q12026-03-31-111.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$152.46K

+499.6%

Gross Profit

-$644.51K

+71.6%

Gross Margin

-4.23%

N/A

Market Cap

$29.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.22M

N/A

Employees

24

N/A

Net Income

-$3.00M

+31.5%

EBITDA

-$2.25M

+46.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$18.52M

+79.3%

Total Debt

$1.61M

-80.6%

Accounts Receivable

$687.76K

+553.5%

Inventory

$0.00

N/A

Long Term Debt

$418.25K

-93.0%

Short Term Debt

$1.20M

-48.4%

Return on Assets

-43.20%

N/A

Return on Invested Capital

-1.78%

N/A

Free Cash Flow

-$5.52M

+1.9%

Operating Cash Flow

-$5.52M

-0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LPTXLeap Therapeutics, Inc.
$0.77-3.15%
ATHAAthira Pharma, Inc.
$6.75-6.12%
HOTHHoth Therapeutics, Inc.
$0.81-4.09%
AIMDAinos, Inc.
$1.65-2.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
NOKNokia
$10.12-0.03%
JOBYJoby Aviation
$7.23-0.01%
SOFISoFi Technologies
$17.28-0.00%

Questions About DARE

What is the current price of Daré Bioscience?

Daré Bioscience is trading at $1.96 per share.

What is the 52-week range for Daré Bioscience?

Over the past 52 weeks, Daré Bioscience has traded between $1.27 and $3.78.

How much debt does Daré Bioscience have?

As of the most recent reporting period, Daré Bioscience reported total debt of $7.18M.

How much cash does Daré Bioscience have on hand?

Daré Bioscience reported $18.52M in cash and cash equivalents in its most recent financial results.

What is Daré Bioscience’s dividend yield?

Daré Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services